Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568202 · ClinicalTrials.gov registry record
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
A clinical trial of Congenital Bleeding Disorder and Haemophilia B, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 449
- Enrollment target
- 1
- Study location
NCT02568202 is a study of Congenital Bleeding Disorder and Haemophilia B that has completed, run by Novo Nordisk A/S. The registered enrollment target is 449 participants, above the 83-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (441% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02568202, a study of Congenital Bleeding Disorder and Haemophilia B, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 449 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is conducted in the United States of America (USA). Tha aim of this study is bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S).
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (1)
New Jersey
- Novo Nordisk Clinical Trial Call Center - Plainsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568202
The ClinicalTrials.gov registry entry for NCT02568202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 8 other Congenital Bleeding Disorder trials with a reported enrollment target (441% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Congenital Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT02568202 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02568202 about?
NCT02568202 is a clinical study titled "Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)". This study is conducted in the United States of America (USA). Tha aim of this study is bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S).
What is the current status of trial NCT02568202?
This trial is currently completed. The enrollment target is 449 participants. The study started on 2015-09. Estimated completion is 2015-11.
What conditions does trial NCT02568202 study?
This clinical trial studies the following conditions: Congenital Bleeding Disorder, Haemophilia B, Haemostasis.
What interventions are being tested in trial NCT02568202?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02568202?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568202 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
COMPLETED · Phase 2
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
COMPLETED · Phase 3
-
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
COMPLETED · Phase 3
-
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.